Performance TechnologiesPTIX
Market Cap: $2.8M
About: Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
Employees: 2
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0% more funds holding
Funds holding: 11 [Q1] → 11 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
8.51% less ownership
Funds ownership: 12.11% [Q1] → 3.59% (-8.51%) [Q2]
99% less capital invested
Capital invested by funds: $12M [Q1] → $146K (-$11.9M) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for PTIX.